Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: BRF113928: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations

 


BRF113928: A Phase II study of the selective BRAF kinase inhibitor GSK2118436 in subjects with advanced non-small cell lung cancer and BRAF mutations


Trial Focus

Lung Cancer

Objective

         This is a clinical trial of GSK2118436 that will be administered by mouth which is investigational.

IRB Protocol #

11-1537

Trial Status

OPEN

Principle Investigator

ROSS CAMIDGE

Sponsor

GlaxoSmithKline

Contact

ANNA WYNFIELD at (720)848-5278 or ANNA.WYNFIELD@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 2 years. A follow up period will consist of phone contact and clinic visits. // Eligibility criteria include but are not limited to 18 years or older with non-small cell lung cancer.Eligibility criteria include but are not limited to 18 years or older with non-small cell lung cancer.